Mk 8353

S100A1 overexpression (ov-S100A1) plasmid (plasmid primer: Forward: 5′-GAAGATTCTAGAGCTAGCGAATTCATGGGCTCTGAGCTGGAG-3′; Reverse: 5′-CGCAGATCCTTGCGGCCGCGGATCCTCAACTGTTCTCCCAGAA-3′) encoding the full-length open reading frame of rat S100A1 and the S100A1 short-interfering (si) RNA plasmid targeting sequence (5′-UGGAGACCCUCAUCAAUGUdTdT-3′) for silencing S1001A (si-S100A1), as well as their corresponding blank plasmid vectors were prepared by Shanghai Genechem Co., Ltd. The overexpression and silencing of S100A1 in PC12 cells were carried out using Lipofectamine^® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. At 48 h post-transfection, the PC12 cells with gene intervention were exposed to LPS and were used in other experiments. In addition, the cells transfected with ov-S100A1 plasmid were treated with the ERK inhibitor, MK-8353 (100 nM, MedChemExpress), 12 h prior to exposure to LPS, as previously described (29 (link)). The cell groups were designed as follows: The control group (without any treatment), LPS group (cells stimulated with 5 µg/ml LPS), LPS + si-S100A1, LPS + ov-S100A1 and ov-S100A1 with MK-8353 treatment (LPS + ov-S100A1 + MK) groups.